Baidu
map

Lancet:2-cm vs 4-cm边缘切除治疗后局部皮肤黑色素瘤

2019-08-12 MedSci MedSci原创

研究认为,2-cm切除边缘对于>2 mm厚局部皮肤黑色素瘤患者的效果与4-cm切除无显著差异

目前对于>2mm的皮肤黑色素瘤患者,最佳的边缘手术切除方案尚不确定。近日研究人员对切除边缘2cm vs 4cm对黑色素瘤患者特异性或整体生存率的长期影响进行了考察。

75岁以下,局部皮肤黑色素瘤厚度大于2 mm患者参与研究,主要部位位于躯干、上肢或下肢。患者随机接受2-cm或4-cm切除边缘的治疗。研究的主要结果是总生存率以及黑色素瘤特异性生存率。

936名患者参与研究,随机分配至4cm边缘(n=465)或2cm切除边缘(n=471)。平均随访19.6年,报告了621例死亡,2-cm组304例(49%),4cm组317例(51%)(未调整HR:0.98)。397人死于皮肤黑色素瘤,其中2cm组192例(48%),4cm组205例(52%)。(未调整HR:0.95)。

研究认为,2-cm切除边缘对于>2 mm厚局部皮肤黑色素瘤患者的效果与4-cm切除无显著差异。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1680630, encodeId=339e1680630c9, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Sat Aug 24 05:22:00 CST 2019, time=2019-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830200, encodeId=f6921830200e5, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Jan 11 20:22:00 CST 2020, time=2020-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405926, encodeId=9d76140592632, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Wed Aug 14 09:22:00 CST 2019, time=2019-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1436013, encodeId=d94f1436013bb, content=<a href='/topic/show?id=c38de2137e4' target=_blank style='color:#2F92EE;'>#皮肤黑色素瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72137, encryptionId=c38de2137e4, topicName=皮肤黑色素瘤)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Aug 14 09:22:00 CST 2019, time=2019-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558979, encodeId=80ba15589e94c, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Wed Aug 14 09:22:00 CST 2019, time=2019-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564988, encodeId=ffb4156498828, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Wed Aug 14 09:22:00 CST 2019, time=2019-08-14, status=1, ipAttribution=)]
    2019-08-24 sunylz
  2. [GetPortalCommentsPageByObjectIdResponse(id=1680630, encodeId=339e1680630c9, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Sat Aug 24 05:22:00 CST 2019, time=2019-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830200, encodeId=f6921830200e5, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Jan 11 20:22:00 CST 2020, time=2020-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405926, encodeId=9d76140592632, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Wed Aug 14 09:22:00 CST 2019, time=2019-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1436013, encodeId=d94f1436013bb, content=<a href='/topic/show?id=c38de2137e4' target=_blank style='color:#2F92EE;'>#皮肤黑色素瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72137, encryptionId=c38de2137e4, topicName=皮肤黑色素瘤)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Aug 14 09:22:00 CST 2019, time=2019-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558979, encodeId=80ba15589e94c, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Wed Aug 14 09:22:00 CST 2019, time=2019-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564988, encodeId=ffb4156498828, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Wed Aug 14 09:22:00 CST 2019, time=2019-08-14, status=1, ipAttribution=)]
    2020-01-11 howi
  3. [GetPortalCommentsPageByObjectIdResponse(id=1680630, encodeId=339e1680630c9, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Sat Aug 24 05:22:00 CST 2019, time=2019-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830200, encodeId=f6921830200e5, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Jan 11 20:22:00 CST 2020, time=2020-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405926, encodeId=9d76140592632, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Wed Aug 14 09:22:00 CST 2019, time=2019-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1436013, encodeId=d94f1436013bb, content=<a href='/topic/show?id=c38de2137e4' target=_blank style='color:#2F92EE;'>#皮肤黑色素瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72137, encryptionId=c38de2137e4, topicName=皮肤黑色素瘤)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Aug 14 09:22:00 CST 2019, time=2019-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558979, encodeId=80ba15589e94c, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Wed Aug 14 09:22:00 CST 2019, time=2019-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564988, encodeId=ffb4156498828, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Wed Aug 14 09:22:00 CST 2019, time=2019-08-14, status=1, ipAttribution=)]
    2019-08-14 chg122
  4. [GetPortalCommentsPageByObjectIdResponse(id=1680630, encodeId=339e1680630c9, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Sat Aug 24 05:22:00 CST 2019, time=2019-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830200, encodeId=f6921830200e5, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Jan 11 20:22:00 CST 2020, time=2020-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405926, encodeId=9d76140592632, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Wed Aug 14 09:22:00 CST 2019, time=2019-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1436013, encodeId=d94f1436013bb, content=<a href='/topic/show?id=c38de2137e4' target=_blank style='color:#2F92EE;'>#皮肤黑色素瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72137, encryptionId=c38de2137e4, topicName=皮肤黑色素瘤)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Aug 14 09:22:00 CST 2019, time=2019-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558979, encodeId=80ba15589e94c, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Wed Aug 14 09:22:00 CST 2019, time=2019-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564988, encodeId=ffb4156498828, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Wed Aug 14 09:22:00 CST 2019, time=2019-08-14, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1680630, encodeId=339e1680630c9, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Sat Aug 24 05:22:00 CST 2019, time=2019-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830200, encodeId=f6921830200e5, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Jan 11 20:22:00 CST 2020, time=2020-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405926, encodeId=9d76140592632, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Wed Aug 14 09:22:00 CST 2019, time=2019-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1436013, encodeId=d94f1436013bb, content=<a href='/topic/show?id=c38de2137e4' target=_blank style='color:#2F92EE;'>#皮肤黑色素瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72137, encryptionId=c38de2137e4, topicName=皮肤黑色素瘤)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Aug 14 09:22:00 CST 2019, time=2019-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558979, encodeId=80ba15589e94c, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Wed Aug 14 09:22:00 CST 2019, time=2019-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564988, encodeId=ffb4156498828, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Wed Aug 14 09:22:00 CST 2019, time=2019-08-14, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1680630, encodeId=339e1680630c9, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Sat Aug 24 05:22:00 CST 2019, time=2019-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830200, encodeId=f6921830200e5, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Jan 11 20:22:00 CST 2020, time=2020-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405926, encodeId=9d76140592632, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Wed Aug 14 09:22:00 CST 2019, time=2019-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1436013, encodeId=d94f1436013bb, content=<a href='/topic/show?id=c38de2137e4' target=_blank style='color:#2F92EE;'>#皮肤黑色素瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72137, encryptionId=c38de2137e4, topicName=皮肤黑色素瘤)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Aug 14 09:22:00 CST 2019, time=2019-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558979, encodeId=80ba15589e94c, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Wed Aug 14 09:22:00 CST 2019, time=2019-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564988, encodeId=ffb4156498828, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Wed Aug 14 09:22:00 CST 2019, time=2019-08-14, status=1, ipAttribution=)]

相关资讯

原发性卵巢恶性黑色素瘤合并成熟性畸胎瘤一例

患者 女,25岁。主因腹胀20d,于2015年12月10日入 本院。患者20d前无明显诱因自觉下腹胀,无明显腹痛,伴 食欲不佳,自以为胃部不适,嚼服健胃消食片1d,下腹胀未 见缓解,就诊于秦皇岛当地医院,行腹部B超检查示:盆腹腔 积液,建议进一步妇科就诊,遂至秦皇岛市妇幼保健院,妇科B超提示子宫右前方实性占位,性质待查,部分腹膜及系膜增 厚,盆腹腔大量腹水,遂住院治疗,给予腹水引流缓解腹胀, 并静

Neon新疫苗“一箭三雕”连破肺癌、膀胱癌、黑色素瘤

“救命神器”天上来!默沙东无人机完成零下70摄氏度低温药品递送Direct Relief组织宣布,由默沙东(MSD)、AT&T、Softbox和Direct Relief联合进行,使用无人机向偏远地区递送需要低温保存的药品和疫苗的概念验证研究获得成功。这一结果可能代表着生物医药物流创新和人道主义活动方面的重要进步。图片来源:默沙东提供对于地处偏远区域或者发生自然灾害地区的人们来说,由于

Targovax宣布在抗PD1难治性黑色素瘤患者中,溶瘤病毒ONCOS-102联合Keytruda取得了令人鼓舞的结果

Targovax ASA生物技术公司,致力于开发针对实体瘤的溶瘤病毒,今天宣布在抗PD1检查点抑制剂难治性晚期黑色素瘤的9名患者中,溶瘤病毒ONCOS-102和Keytruda组合导致患者的总反应率(ORR)为33%。

枯木逢春:氟苯达唑或能有效抑制黑色素瘤的生长和扩散

近日,来自澳大利亚新南威尔士大学的科学家们通过研究发现,一种使用了将近40年,用于治疗人类和动物蠕虫感染的药物或能用来抑制小鼠机体中黑色素瘤的生长和扩散,在欧洲这种药物是一种非处方药物,通常能用来抗蠕虫控制患者机体的寄生虫感染。图片来源:University of New South Wales这种药物名为氟苯达唑(flubendazole),其能有效抑制小鼠机体中人类肿瘤的生长和转移,研究者Le

Scancell的DNA肿瘤疫苗治疗黑色素瘤将开展2期临床试验

Scancell ImmunoBody公司宣布其黑色素瘤新药SCIB1(T细胞加强免疫疗法)将在几周后于英国开展2期临床试验。

不可切除或转移性晚期黑色素瘤的治疗或再迎新药:评估masitinib的III期试验

AB Science近日报道了一项III期试验(AB08026研究)的分析,该试验评估了masitinib治疗不可切除或转移的3期或4期黑色素瘤患者(c-Kit的JM结构域突变)的有效性和安全性,并与达卡巴嗪作比较。该研究的主要终点是总体反应率(ORR)。

Baidu
map
Baidu
map
Baidu
map